Systematic analytical validation of commercial kits for the determination of novel biomarkers for clinical drug development

Bioanalysis

Volumn 2, Issue 2, 2010, Pages 237-247

  Nowatzke, William ^a   Cole, Thomas G ^b   Bowsher, Ronald R ^c  

^a CEDRA Corporation   (United States)

^b Thom Cole Consulting   (United States)

^c Millipore Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANALYTICAL EQUIPMENT; CLINICAL RESEARCH; DECISION MAKING; DIAGNOSTIC TEST; DRUG DEVELOPMENT; FEASIBILITY STUDY; FOOD AND DRUG ADMINISTRATION; HUMAN; LABORATORY TEST; NONHUMAN; QUANTITATIVE ANALYSIS; REVIEW; STANDARD; VALIDATION STUDY; ANIMAL; CLINICAL CHEMISTRY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; INSTRUMENTATION; METHODOLOGY; REPRODUCIBILITY;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL CHEMISTRY TESTS; CLINICAL LABORATORY TECHNIQUES; DRUG DISCOVERY; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 79952509066     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.191     Document Type: Review

References (22)

1. Lee JW, Smith WC, Nordblom GD, Bowsher RR. Validation of assays for the bioanalysis of novel biomarkers. In: Biomarkers in Clinical Drug Development. Bloom JC and Dean RA (Eds). Marcel Dekker, NY, USA, 119-149 (2003).
2. Woodcock J. Chutes and ladders on the critical path: comparative effectiveness, product value, and the use of biomarkers in drug development. Clin. Pharmacol. Ther. 86(1), 12-14 (2009).
3. Colburn WA. Biomarkers in drug discovery and development: from target identification through drug marketing. J. Clin. Pharmacol. 43(4), 329-341 (2003). (Pubitemid 36368776)
4. Williams SA, Slavin DE, Wagner JA, Webster CJ. A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nat. Rev. Drug Discov. 5(11), 897-902 (2006). (Pubitemid 44660603)
5. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Ther. 81(1), 104-7 (2007). (Pubitemid 46050874)
6. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24(8), 971-83 (2006). (Pubitemid 44215392)
7. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Pharm. Res. 9, 588-592 (1992).
8. Guidance for Industry On Bioanalytical Method Validation. Federal Register 66, 28526-28527 (2001).
9. Viswanathan CT, Bansal S, Booth B, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-73 (2007). (Pubitemid 47389236)
10. Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23, 312-328 (2006). (Pubitemid 43237862)
11. Bowsher RR, Sailstad JM. Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug metabolism: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor kb ligand. J. Pharm. Biomed. Anal. 48, 1282-1289 (2008).
12. Chau CH, Rixie O, McLeod H, et al. Validation of analytical methods for biomarkers used in drug development. Clin. Cancer Res. 14(19), 5967-5976 (2008).
13. Lee JW, Hall M. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J. Chromatrogr. B 877, 1259-1271 (2009).
14. Bowsher RR. Analytical validation of assays for novel biomarkers. Presented at: AAPS Workshop, Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development. Salt Lake City, UT, USA (2003).
15. AAPS Workshop. Biomarker Assay Development and Validation: Challenges and Creative Solutions Associated with Emerging Biomarker Assays. Georgia World Congress Center, Atlanta, GA, USA, 15-16 November (2008).
16. Lee JW, Weiner RS, Sailstad JM, et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development. A conference report. Pharm. Res. 22, 499-511 (2005). (Pubitemid 40603246)
17. Westgard JO, Barry PL, Hunt MR, Groth T. A multi-rule shewhart chart for quality control in clinical chemistry. Clin. Chem. 27, 493-501 (2001).
18. Wang J, Lee J, Burns D, et al. "Fit-for-purpose" method validation and application of a biomarker (c-terminal telopeptides of type 1 collagen) in denosumab clinical studies. AAPS J. 11(2), 385-394 (2009).
19. Bunk DM. Reference materials and reference measurement procedures: an overview from a national metrology institute. Clin. Biochem. Rev. 28, 131-137 (2007).
20. Department of Health and Human Services, Food and Drug Administration. 42 CFR Part 493, Laboratory Requirements, Section 2 Definitions (2004).
21. Department of Health and Human Services, US FDA, 42 CFR Part 493, Laboratory Requirements, Section 1253, Standard: establishment and verification of performance specifications (2004).
22. US FDA. Innovation or stagnation? Challenge and opportunity on the critical path to new medical products www.fda.gov/ohrms/dockets/ac/04/briefing/ 4039b1-03-Critical%20Path%20 whitepaper.pdf